Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,554,032 shares of the medical equipment provider’s stock after acquiring an additional 18,774 shares during the quarter. The Manufacturers Life Insurance Company owned about 1.10% of Hologic worth $208,051,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Swedbank AB bought a new position in Hologic in the 1st quarter worth approximately $120,827,000. Black Creek Investment Management Inc. grew its stake in shares of Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp increased its holdings in shares of Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after purchasing an additional 815,960 shares during the period. Marshall Wace LLP bought a new stake in shares of Hologic during the second quarter valued at about $39,427,000. Finally, Hsbc Holdings PLC raised its stake in shares of Hologic by 14.6% during the second quarter. Hsbc Holdings PLC now owns 2,034,651 shares of the medical equipment provider’s stock valued at $151,100,000 after purchasing an additional 259,185 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. UBS Group lifted their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Leerink Partners decreased their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Raymond James boosted their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Stock Performance

HOLX stock opened at $79.00 on Wednesday. The stock has a market cap of $18.35 billion, a P/E ratio of 23.72, a P/E/G ratio of 2.51 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The firm has a 50 day simple moving average of $80.38 and a 200 day simple moving average of $78.38. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the previous year, the company posted $0.89 EPS. Hologic’s revenue was up 4.5% on a year-over-year basis. Research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.